Dyne Therapeutics to Present at October Investor Conferences
28 Setembro 2023 - 8:30AM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases,
today announced that management is scheduled to present at the
following investor conferences in October:
- Chardan’s
7th Annual Genetic Medicines
Conference, fireside chat on Tuesday, October 3, 2023 at
11:00 a.m. ET in New York
- Jefferies Inaugural Biotech CNS/Neuro Summit,
fireside chat on Thursday, October 12, 2023 at 9:30 a.m. ET in New
York
A live webcast of each presentation will be available in the
Investors & Media section of Dyne’s website at
https://investors.dyne-tx.com/news-and-events/events-and-presentations
and a replay will be accessible for 90 days.
About Dyne TherapeuticsDyne Therapeutics is a
clinical-stage muscle disease company focused on advancing
innovative life-transforming therapeutics for people living with
genetically driven diseases. With its proprietary FORCE™ platform,
Dyne is developing modern oligonucleotide therapeutics that are
designed to overcome limitations in delivery to muscle tissue. Dyne
has a broad pipeline for serious muscle diseases, including
clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne
muscular dystrophy (DMD) and a preclinical program for
facioscapulohumeral muscular dystrophy (FSHD). For more
information, please visit https://www.dyne-tx.com/, and follow us
on Twitter, LinkedIn and Facebook.
Contact:
Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com 857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024